[Comparative studies of antitumor activities of oxalate (1R, 2R-cyclohexanediammine) platinum (II) and cis-dichlorodiammine-platinum (II) using ovarian cancer transplanted into nude mice].
A new platinum coordination complex, l-OHP [oxalato (1R, 2R-cyclohexanediammine) platinum (II)], has been shown to be an active anticancer agent in animals. In the present study comparisons of the effects on human ovarian carcinomas transplanted into nude mice (OCl-1-N, OS-4-N, OY-1-N) between l-OHP and CDDP, were investigated. l-OHP (6 mg/kg, 9 mg/kg) and CDDP (3 mg/kg, 6 mg/kg) were administered intraperitoneally in a schedule of every four days for three doses. Simultaneously the tumor size and the body weight were measured and the peripheral WBC and serum BUN were examined. The results were as follows: 1) The antitumor activity of l-OHP corresponded to that of CDDP in proportion to the Pt content and mouse LD50. 2) In l-OHP, there was no elevation of the BUN value and less decrease in body weight, but the peripheral leukopenia was more severe, although reversible. l-OHP is an active anticancer agent against xenografts in nude mice and is strongly recommended for clinical application.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000187:drug effects; D002945:Cisplatin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D000077150:Oxaliplatin
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002945:Cisplatin